retatrutide 0.5mg Medscape | Retatrutide, Eli Lilly's first-in-class triple hormone receptor agonist, delivered meaningful weight loss at 80 weeks in all doses in the VisualAbstract: Retatrutide reduces body weight

It also makes interactions with the thumb-and-forefinger (TaF) domain, including a likely H-bond with Gln4216

Phase 2 data (Jastreboff et al., NEJM 2023) showed mean pulse rate increases of approximately 3 to 5 beats per minute at higher doses, consistent with known GLP-1 receptor agonist pharmacology

More information Harvard Medical School has more on the potential side effects of GLP-1 drugs

By slowing down gastric emptying and increasing feelings of fullness, GLP-1 medications have been shown to help individuals eat less and lose weight over time

Appetite regulation and satiety enhancement Semaglutide acts on GLP-1 receptors in the brain, particularly in areas like the hypothalamus that control hunger and satiety